Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NVCR | NovoCure Limited

Healthcare | Medical Devices | United Kingdom | NASD

Index	-	P/E	-	EPS (ttm)	-1.65	Insider Own	1.00%	Shs Outstand	106.29M	Perf Week	-10.10%
Market Cap	1.88B	Forward P/E	-	EPS next Y	-5.38	Insider Trans	-0.24%	Shs Float	105.32M	Perf Month	-42.05%
Income	-174.40M	PEG	-	EPS next Q	-0.53	Inst Own	80.70%	Short Float / Ratio	8.74% / 5.17	Perf Quarter	-58.46%
Sales	507.70M	P/S	3.70	EPS this Y	-56.70%	Inst Trans	2.93%	Short Interest	9.21M	Perf Half Y	-69.46%
Book/sh	3.91	P/B	4.44	EPS next Y	-155.70%	ROA	-14.80%	Target Price	58.71	Perf Year	-77.76%
Cash/sh	8.68	P/C	2.00	EPS next 5Y	-	ROE	-40.20%	52W Range	17.14 - 120.03	Perf YTD	-76.35%
Dividend	-	P/FCF	-	EPS past 5Y	4.10%	ROI	-10.00%	52W High	-85.55%	Beta	0.66
Dividend %	-	Quick Ratio	6.90	Sales past 5Y	24.90%	Gross Margin	75.90%	52W Low	1.23%	ATR	1.23
Employees	1320	Current Ratio	7.10	Sales Q/Q	-10.50%	Oper. Margin	-37.50%	RSI (14)	21.95	Volatility	3.67% 5.40%
Optionable	Yes	Debt/Eq	1.36	EPS Q/Q	-135.40%	Profit Margin	-34.30%	Rel Volume	0.58	Prev Close	17.59
Shortable	Yes	LT Debt/Eq	1.36	Earnings	Jul 27 BMO	Payout	-	Avg Volume	1.78M	Price	17.35
Recom	2.30	SMA20	-17.13%	SMA50	-39.18%	SMA200	-70.94%	Volume	1,039,222	Change	-1.36%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-28-23	Downgrade	H.C. Wainwright	Buy → Neutral	$85 → $25
Aug-08-23	Upgrade	Piper Sandler	Neutral → Overweight	$45
Aug-04-23	Initiated	SVB Securities	Outperform	$51
Jul-31-23	Upgrade	Evercore ISI	Underperform → In-line	$33
Jun-07-23	Upgrade	Wedbush	Underperform → Neutral	$53 → $46
May-16-23	Upgrade	Wells Fargo	Equal Weight → Overweight	$70 → $104
Mar-17-23	Downgrade	JP Morgan	Neutral → Underweight	$99 → $50
Jan-06-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$89 → $107
Jan-05-23	Reiterated	H.C. Wainwright	Buy	$100 → $140
Nov-29-22	Upgrade	Wells Fargo	Equal Weight → Overweight	$74 → $89
Oct-24-22	Downgrade	Piper Sandler	Overweight → Neutral	$90 → $70
Jul-05-22	Downgrade	Evercore ISI	In-line → Underperform
May-16-22	Initiated	H.C. Wainwright	Buy	$115
Feb-08-22	Initiated	Loop Capital	Buy	$200
Feb-02-22	Upgrade	Oppenheimer	Perform → Outperform	$98
Jan-20-22	Upgrade	Truist	Hold → Buy	$125
Jan-03-22	Upgrade	Evercore ISI	Underperform → In-line	$82
Jul-01-21	Downgrade	Mizuho	Buy → Neutral
Apr-14-21	Downgrade	Wedbush	Neutral → Underperform	$159 → $154
Jan-25-21	Reiterated	Piper Sandler	Overweight	$140 → $225

Show Previous Ratings

Sep-18-23 11:47AM	Should You Hold NovoCure Limited (NVCR)? (Insider Monkey)
Sep-08-23 04:01PM	Novocure Highlights Use of Tumor Treating Fields Therapy in Treatment of Non-Small Cell Lung Cancer at 2023 World Conference on Lung Cancer (Business Wire)
Sep-06-23 02:27PM	3 Healthcare Stocks to Sell in September Before They Crash & Burn (InvestorPlace)
Sep-04-23 09:30AM	Down 31% in 1 Day, What's Next for NovoCure Stock? (Motley Fool)
Aug-31-23 06:52PM	Why Novocure Stock Fell 24.4% This Week (Motley Fool)
09:55AM	Loading…
09:55AM	Is NovoCure's Stock Headed for a Free Fall? (Motley Fool)
Aug-29-23 06:31PM	Novocure Announces The Lancet Oncology Publishes Primary Data from Phase 3 LUNAR Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies (Business Wire) +8.84%
Aug-28-23 05:15PM	Novocure Shares Plunge After Its Ovarian Cancer Treatment Fails to Meet Goal (Investopedia) -37.50%
04:08PM	Novocure Plummets 38% After Its Treatment For Ovarian Cancer Fails (Investor's Business Daily)
02:19PM	Novocure Plummets 35% After Its Cancer Treatment Fails In Ovarian Cancer (Investor's Business Daily)
12:21PM	Why NovoCure Stock Is Crashing Today (Motley Fool)
12:16PM	3M, Boston Scientific rise; Abcam, NovoCure fall, Monday, 8/28/2023 (AP Finance)
12:10PM	NovoCure Ltd (NVCR): A Deep Dive into Its Performance Potential (GuruFocus.com)
11:47AM	NovoCure (NVCR): A Smart Investment or a Value Trap? An In-Depth Exploration (GuruFocus.com)
09:34AM	Midday movers: 3M, XPeng, Hawaiian Electric Industries and more (Investing.com)
09:07AM	Loading…
09:07AM	Novocure Plummets 34% After Its Cancer Treatment Fails In Ovarian Cancer (Investor's Business Daily)
09:07AM	Novocure Plummets 32% After Its Cancer Treatment Fails In Ovarian Cancer (Investor's Business Daily)
07:27AM	UPDATE 1-Novocure's cancer therapy fails to meet main goal in late-stage trial (Reuters)
07:10AM	Novocure says its ovarian cancer therapy did not meet main goal in late-stage trial (Reuters)
07:00AM	Novocure Provides Update on Phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 Trial Evaluating Tumor Treating Fields Therapy in Platinum-resistant Ovarian Cancer (Business Wire)
Aug-25-23 08:20AM	Could NovoCure Stock Help You Become a Millionaire? (Motley Fool)
07:00AM	Novocure to Participate in Upcoming Investor Conferences (Business Wire)
Aug-15-23 09:30AM	Accuray's (ARAY) Treatment Options to be Boosted Post FDA's Nod (Zacks)
Aug-13-23 05:49PM	15 Worst Performing Healthcare Stocks in 2023 (Insider Monkey)
Aug-09-23 10:45AM	2 Incredibly Cheap Growth Stocks to Buy in August (Motley Fool) +7.13%
05:10AM	Is NovoCure Stock a Buy Now? (Motley Fool)
Aug-08-23 04:11PM	Why Novocure Was a Healthy Stock Today (Motley Fool)
10:02AM	DraftKings upgraded, Home Depot downgraded: Wall Street's top analyst calls (The Fly)
Aug-04-23 09:38AM	Apple downgraded, Amazon upgraded: Wall Street's top analyst calls (The Fly)
Aug-01-23 03:54PM	10 Oversold NASDAQ Stocks to Buy (Insider Monkey)
06:56PM	Loading…
Jul-27-23 06:56PM	Why Novocure Stock Tumbled by Nearly 16% Today (Motley Fool) -15.89%
11:30AM	NovoCure (NVCR) Q2 2023 Earnings Call Transcript (Motley Fool)
08:15AM	NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:07AM	NovoCure: Q2 Earnings Snapshot (AP Finance)
07:00AM	Novocure Reports Second Quarter 2023 Financial Results (Business Wire)
Jul-25-23 10:01AM	Earnings Preview: Revvity (RVTY) Q2 Earnings Expected to Decline (Zacks)
Jul-21-23 08:00AM	Novocure Announces Favorable Independent Data Monitoring Committee Recommendation to Continue Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields Therapy in Pancreatic Cancer (Business Wire)
Jul-06-23 01:17PM	Here's Why Novocure Stock Dropped 42% in June (Motley Fool)
Jul-03-23 08:00AM	Novocure to Report Second Quarter 2023 Financial Results (Business Wire)
Jun-12-23 09:30AM	3 Small-Cap Drug Stocks to Watch as Their Clinical Trials End Soon (InvestorPlace)
05:39AM	This Beaten-Down Growth Stock Has 99% Upside, According to Wall Street (Motley Fool)
Jun-09-23 09:45AM	Novocure Breaks a Major Support Zone: What Now? (TheStreet.com) -6.02%
Jun-07-23 11:05AM	Why Shares of Zai Lab Are Dropping Wednesday (Motley Fool)
Jun-06-23 04:02PM	Novocure Crashes 43% As Critics Question Its 'Profound' Impact In Lung Cancer Treatment (Investor's Business Daily) -43.04%
04:01PM	Novocure Stock Gets Relative Strength Rating Upgrade, Then Drops +40% (Investor's Business Daily)
03:40PM	Novocure's Cancer Treating Electric Fields Improves Survival In Lung Cancer Patients, But Stock Tumbles On Remaining Doubts (Benzinga)
02:48PM	These 2 Nasdaq Stocks Are Plunging. Here's Why (Motley Fool)
12:11PM	Novocure Crashes 32% As Critics Question Its 'Profound' Impact In Lung Cancer Treatment (Investor's Business Daily)
11:50AM	Why NovoCure Stock Is Crashing Today (Motley Fool)
10:31AM	Novocure Crashes Almost 30% As Critics Question Its 'Profound' Impact In Lung Cancer Treatment (Investor's Business Daily)
08:31AM	UPDATE 2-Novocure's lung cancer device extends survival in late-stage study (Reuters)
08:12AM	REFILE-Novocure lung cancer therapy extends survival in study (Reuters)
08:05AM	Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies (GlobeNewswire)
08:00AM	LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies (Business Wire)
Jun-01-23 07:01AM	Novocure Pledges $3 Million to Conquer Cancer®, the ASCO Foundation, to Support Cancer Research and Education (Business Wire)
May-27-23 06:14AM	3 No-Brainer Stocks to Buy for Under $100 Right Now (Motley Fool)
May-05-23 09:54AM	NovoCure Limited's (NASDAQ:NVCR) Business Is Trailing The Industry But Its Shares Aren't (Simply Wall St.)
05:51AM	Should You Buy Novocure Stock Right Now? (Motley Fool)
May-04-23 01:00PM	NovoCure (NVCR) Q1 2023 Earnings Call Transcript (Motley Fool)
08:35AM	NovoCure (NVCR) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:32AM	NovoCure: Q1 Earnings Snapshot (AP Finance)
07:00AM	Novocure Reports First Quarter 2023 Financial Results (Business Wire)
Apr-26-23 05:59PM	The 3 Most Promising Healthcare Tech Stocks for April 2023 (InvestorPlace) +5.09%
10:01AM	Novocure Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (Business Wire)
Apr-14-23 08:27AM	Novocure Announces 27 Presentations, Including Real-World Evidence and Preclinical Research, at American Association for Cancer Research (AACR) Annual Meeting 2023 (Business Wire)
Apr-06-23 06:40AM	NovoCure (NASDAQ:NVCR) shareholder returns have been solid, earning 194% in 5 years (Simply Wall St.)
Apr-03-23 08:00AM	Novocure to Report First Quarter 2023 Financial Results (Business Wire)
Mar-29-23 04:40PM	12 Most Promising Healthcare Stocks According to Analysts (Insider Monkey)
07:30AM	Kristin Stafford Joins Novocure Board of Directors (Business Wire)
Mar-16-23 12:48PM	Institutional investors may adopt severe steps after NovoCure Limited's (NASDAQ:NVCR) latest 7.3% drop adds to a year losses (Simply Wall St.)
07:30AM	Novocure Announces 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program (Business Wire)
Mar-08-23 06:00PM	2 Best Defensive Stocks to Buy in March (Motley Fool)
Mar-01-23 07:01AM	Novocure Announces Reimbursement of Optune® for the Treatment of Newly Diagnosed Glioblastoma in France (Business Wire)
07:00AM	Novocure Announces Last Patient Enrolled in Pivotal METIS Study of Tumor Treating Fields in Brain Metastases from Non-Small Cell Lung Cancer (Business Wire)
Feb-24-23 05:35AM	NovoCure Full Year 2022 Earnings: US$0.88 loss per share (vs US$0.56 loss in FY 2021) (Simply Wall St.)
Feb-23-23 01:44PM	Why NovoCure Stock Is Falling Today (Motley Fool)
10:30AM	NovoCure (NVCR) Q4 2022 Earnings Call Transcript (Motley Fool)
09:35AM	NovoCure (NVCR) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Novocure Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update (Business Wire)
07:00AM	Allyson J. Ocean, M.D., Joins Novocure Board of Directors (Business Wire)
Feb-16-23 10:01AM	Analysts Estimate NovoCure (NVCR) to Report a Decline in Earnings: What to Look Out for (Zacks)
Feb-15-23 06:22PM	Why Novocure Stock Was so Healthy Today (Motley Fool)
07:00AM	Novocure Announces Last Patient Enrolled in Pivotal PANOVA-3 Study of Tumor Treating Fields in Pancreatic Cancer (Business Wire)
Feb-10-23 05:16AM	Should You Investigate NovoCure Limited (NASDAQ:NVCR) At US$87.50? (Simply Wall St.)
Jan-26-23 09:00AM	Why Investors Need to Take Advantage of These 2 Medical Stocks Now (Zacks)
Jan-24-23 09:00AM	How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings (Zacks)
Jan-19-23 04:09PM	Novocure Round-Trips Its Recent Breakout After Announcing A Series Of C-Suite Changes (Investor's Business Daily) -5.17%
11:36AM	Why Novocure Stock Is Sliding Today (Motley Fool)
07:30AM	Novocure Announces Organizational Changes to Prepare for Future Growth (Business Wire)
06:01AM	Will Novocure Stock Sink or Soar in 2023? (Motley Fool)
Jan-17-23 04:07PM	Novocure Has Fallen More Than 22% Over Seven Days Why It Fell From Grace (Investor's Business Daily)
Jan-09-23 11:37AM	Why Novocure Stock Is Sinking Today (Motley Fool) -16.32%
07:00AM	Novocure Announces Preliminary Full Year and Fourth Quarter 2022 Net Revenues and Provides Company Update (Business Wire)
Jan-07-23 06:31AM	Is NovoCure a Good Stock to Buy Right Now? (Motley Fool)
Jan-06-23 06:15AM	Why Novocure Stock Is Flying High (Motley Fool) -8.22%
Jan-05-23 04:46PM	Novocure Skyrockets 69% After Pulling Off A Once-In-Six-Years Feat (Investor's Business Daily) +68.45%
04:02PM	Novocure Skyrockets After Pulling Off A Once-In-Six-Years Feat (Investor's Business Daily)
03:50PM	Why Shares of Zai Lab Soared This Week (Motley Fool)
10:52AM	Why Novocure Stock Is Skyrocketing Today (Motley Fool)
10:21AM	Novocure Stock Surges As Tumor Treating Fields Shows Overall Survival In Lung Cancer Patients (Benzinga)

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. The company was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cordova Ashley	Chief Financial Officer	Sep 01	Sale	21.82	883	19,265	99,650	Sep 05 04:24 PM
GROENHUYSEN WILHELMUS CM	Chief Operating Officer	Sep 01	Sale	21.82	294	6,414	209,825	Sep 05 04:24 PM
Shah Pritesh	Chief Growth Officer	Sep 01	Sale	21.82	273	5,956	124,893	Sep 05 04:23 PM
Cordova Ashley	Chief Financial Officer	Aug 02	Sale	30.25	1,144	34,607	100,533	Aug 04 04:02 PM
Leonard Frank X	President, CNS Cancers US	Mar 07	Sale	75.16	8,318	625,205	54,284	Mar 07 04:52 PM
GROENHUYSEN WILHELMUS CM	Chief Operating Officer	Mar 03	Sale	76.16	25,635	1,952,346	209,753	Mar 07 04:51 PM
Shah Pritesh	Chief Growth Officer	Mar 03	Sale	76.16	21,421	1,631,411	124,799	Mar 07 04:52 PM
Cordova Ashley	Chief Financial Officer	Mar 03	Sale	76.16	5,505	419,257	101,310	Mar 07 04:51 PM
Leonard Frank X	President, CNS Cancers US	Mar 03	Sale	76.16	5,291	402,959	62,602	Mar 07 04:52 PM
Leonard Frank X	President, CNS Cancers US	Mar 03	Sale	77.64	2,059	159,859	67,893	Mar 06 04:37 PM
Burke William Patrick	Chief Human Resources Officer	Mar 03	Sale	76.16	593	45,163	66,090	Mar 07 04:50 PM
Leonard Frank X	President, CNS Cancers US	Mar 02	Sale	75.38	4,107	309,578	58,988	Mar 03 04:13 PM
GROENHUYSEN WILHELMUS CM	Chief Operating Officer	Mar 02	Sale	75.28	1,213	91,312	183,402	Mar 06 04:40 PM
Cordova Ashley	Chief Financial Officer	Mar 02	Sale	75.28	1,055	79,418	95,007	Mar 06 04:40 PM
Shah Pritesh	Chief Growth Officer	Mar 02	Sale	75.28	937	70,535	99,038	Mar 06 04:41 PM
Leonard Frank X	President, CNS Cancers US	Mar 02	Sale	75.28	844	63,535	58,144	Mar 06 04:37 PM
Burke William Patrick	Chief Human Resources Officer	Mar 02	Sale	75.28	281	21,153	66,683	Mar 06 04:42 PM
Cordova Ashley	Chief Financial Officer	Mar 01	Sale	76.36	2,198	167,845	96,062	Mar 02 04:55 PM
GROENHUYSEN WILHELMUS CM	Chief Operating Officer	Mar 01	Sale	76.36	2,164	165,248	184,615	Mar 02 04:49 PM
Shah Pritesh	Chief Growth Officer	Mar 01	Sale	76.36	1,923	146,845	99,975	Mar 02 05:00 PM
Leonard Frank X	President, CNS Cancers US	Mar 01	Sale	76.36	1,684	128,594	63,095	Mar 02 05:01 PM
Burke William Patrick	Chief Human Resources Officer	Mar 01	Sale	76.36	755	57,654	66,964	Mar 02 04:51 PM
Danziger Asaf	Chief Executive Officer	Jan 05	Option Exercise	7.66	212,500	1,627,125	201,083	Jan 09 06:18 PM
Leonard Frank X	President, CNS Cancers US	Jan 05	Option Exercise	15.39	35,209	541,697	53,984	Jan 09 06:21 PM
Weinberg Uri	Chief Science Officer	Jan 05	Option Exercise	47.04	1,946	91,540	49,050	Jan 09 06:24 PM
Danziger Asaf	Chief Executive Officer	Jan 05	Sale	108.74	212,500	23,106,230	13,583	Jan 09 06:18 PM
Leonard Frank X	President, CNS Cancers US	Jan 05	Sale	112.25	39,507	4,434,654	46,158	Jan 09 06:21 PM
Weinberg Uri	Chief Science Officer	Jan 05	Sale	116.14	8,143	945,756	43,286	Jan 09 06:24 PM
Shah Pritesh	Chief Commercial Officer	Jan 05	Sale	108.00	387	41,796	82,843	Jan 09 06:20 PM
Cordova Ashley	Chief Financial Officer	Dec 02	Option Exercise	7.15	2,000	14,300	74,376	Dec 05 04:33 PM
Leonard Frank X	President, CNS Cancers US	Oct 13	Sale	76.01	6,754	513,372	43,626	Oct 17 04:35 PM
Leonard Frank X	President, CNS Cancers US	Oct 06	Sale	84.37	6,754	569,835	50,380	Oct 07 04:16 PM
Leonard Frank X	President, CNS Cancers US	Sep 29	Sale	77.35	6,754	522,422	57,134	Sep 30 04:20 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NVCR | NovoCure Limited

Upgrade your FINVIZ experience